Business
Moderna and Metagenomi Establish Collaboration to Develop Next-Generation In Vivo Gene Editing Therapeutics
The collaboration will combine Metagenomi’s next-generation CRISPR-based and other novel gene editing systems with Moderna’s mRNA and LNP technologies to
About this update from Moderna, Inc.
[{"type":"text","content":"\nThe collaboration will combine Metagenomi’s next-generation CRISPR-based and other novel gene editing systems with Moderna’s mRNA and LNP technologies to accelerate the development of in vivo gene editing therapeutics\n\nMulti-year research collaboration funded by Moderna covering a series of undisclosed disease targets\n\nMetagenomi to receive up-front cash payment, equity investment, and research funding, with potential for additional research, milestone and royalty payments\n\n CAMBRIDGE, Mass. & EMERYVILLE, Calif.--(BUSINESS WIRE)--\nModerna Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines and Metagenomi, Inc., a genetic medicines company with a versatile portfolio of next-generation gene editing tools, today announced that the two companies have entered into a strategic research and development collaboration focused on advancing new gene editing systems for in vivo human therapeutic applications. The collaboration will utilize Metagenomi’s novel gene editing tools and leverage Moderna’s mRNA platform, as well as lipid nanoparticle (LNP) delivery technologies, with the goal of developing curative therapies for patients with serious genetic diseases.\n\n“Metagenomi has demonstrated the power of its proprietary metagenomics approach that mines the Earth’s natural environment to discover next-generation gene editing tools and has developed discovery capabilities with the potential to address multiple diseases,” said Eric Huang, PhD, General Manager & Chief Scientific Officer, Moderna Genomics (mGx). “Their discovery platform and expertise will expand Moderna Genomics’ ongoing efforts to develop innovative in vivo gene editing therapies to address a significant unmet medical need. This collaboration represents another milestone on our journey to create transformational genome-engineering based medicines.”\n\n“Gene editing has the potential to provide a cure for millions of patients living with genetic disease. Our partnership with Moderna is designed to accelerate the creation of genetic medicines using Metagenomi’s naturally derived, compact, modular and precise gene editing systems,” said Brian C. Thomas, PhD, CEO and Co-Founder of Metagenomi. “This partnership will enhance our shared vision to forge transformative therapeutics for patients.”\n\n“Unlocking the therapeutic ...